LifeMD, Inc. (NASDAQ:LFMD) CEO Sells $129,750.00 in Stock

LifeMD, Inc. (NASDAQ:LFMD) CEO Justin Schreiber sold 25,000 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $5.19, for a total value of $129,750.00. Following the completion of the transaction, the chief executive officer now directly owns 2,703,715 shares of the company’s stock, valued at approximately $14,032,280.85. This trade represents a 0.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Justin Schreiber also recently made the following trade(s):

• On Monday, December 2nd, Justin Schreiber sold 25,000 shares of LifeMD stock. The stock was sold at an average price of $6.52, for a total value of $163,000.00.

LifeMD Trading Up 0.5 %

Shares of NASDAQ:LFMD traded up $0.03 during trading on Monday, reaching $5.78. The company’s stock had a trading volume of 799,608 shares, compared to its average volume of 769,636. The firm’s 50 day simple moving average is $5.50 and its two-hundred day simple moving average is $5.58. The company has a current ratio of 0.83, a quick ratio of 0.78 and a debt-to-equity ratio of 10.83. LifeMD, Inc. has a 12 month low of $3.99 and a 12 month high of $12.88. The stock has a market capitalization of $250.34 million, a PE ratio of -9.03 and a beta of 1.49.

Wall Street Analysts Forecast Growth

LFMD has been the topic of several research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 target price on shares of LifeMD in a report on Friday, September 20th. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of LifeMD in a report on Monday, November 11th. Mizuho assumed coverage on LifeMD in a report on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 target price on the stock. Finally, Lake Street Capital assumed coverage on LifeMD in a research note on Tuesday, December 10th. They set a “buy” rating and a $12.00 price target for the company. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.57.

Institutional Investors Weigh In On LifeMD

Institutional investors have recently modified their holdings of the stock. Los Angeles Capital Management LLC raised its holdings in LifeMD by 852.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 121,585 shares of the company’s stock valued at $637,000 after buying an additional 108,822 shares during the period. State Street Corp increased its position in LifeMD by 20.0% during the third quarter. State Street Corp now owns 1,155,495 shares of the company’s stock valued at $6,055,000 after acquiring an additional 192,861 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of LifeMD in the second quarter valued at $93,000. Centiva Capital LP bought a new stake in shares of LifeMD in the 3rd quarter worth about $196,000. Finally, Royce & Associates LP boosted its stake in shares of LifeMD by 14.6% during the 3rd quarter. Royce & Associates LP now owns 901,041 shares of the company’s stock worth $4,721,000 after purchasing an additional 114,710 shares during the period. 35.52% of the stock is owned by institutional investors.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.